Procalcitonin implication in renal cell apoptosis induced by acute pyelonephritis in children by Belhadj-Tahar, Hafid et al.
© 2008 Belhadj-Tahar et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Infection and Drug Resistance 2008:1 17–20 17
ORIGINAL RESEARCH
Procalcitonin implication in renal cell apoptosis 
induced by acute pyelonephritis in children
Hafid Belhadj-Tahar1,2
Yvon Coulais2
Mathieu Tafani2
François Bouissou3
1Groupe Santé Recherche, Toulouse, 
France; 2EA 3033 Université Paul 
Sabatier III, Toulouse, France; 3Service 
de Néphrologie Pédiatrique, CHU 
Purpan, Toulouse, France
Correspondence: Haﬁ  d Belhadj-Tahar
Groupe Santé Recherche, 35 Bernard 
de Ventadour, 31300 Toulouse (France)
Tel +33 5 61 49 20 30
Fax +33 5 61 49 20 40
Email belhadj.h@chu-toulouse.fr
Abstract: The aim of this biomedical trial was to clarify the physiological role of procalcitonin 
(PCT) in renal parenchyma apoptosis and ﬁ  brosis caused by acute childhood pyelonephritis. This 
prospective study enrolled 183 children. All children were treated with bi-therapy according 
to the French consensus on acute pyelonephritis treatment dated November 16, 1990: intra-
vascular administration of ceftriaxone 50 mg/kg/day and netromicine 7 mg/kg/day during the 
ﬁ  rst 48 hours, followed by speciﬁ  c antibiotherapy suited to antibiogram. On admission, PCT, 
C-reactive protein, and phospholipase A2 were quantiﬁ  ed in serum. Scintigraphy monitoring 
with 99mTc-DMSA was performed on day 4 and 9 months later, in the presence of persistent 
abnormalities. On day 4, 78% presented renal parenchyma alterations and 30% renal ﬁ  brosis 
9 months after admission. Paradoxically, PCT level was signiﬁ  cantly lower in the presence of 
renal ﬁ  brosis due to cell apoptosis (4.19 vs 7.59 µgL-1). A signiﬁ  cant increase in PCT indicated 
favorable progress (recovery 7.55 vs aggravation 3.34) and no difference between recovery 
and improvement. This result suggests the protective effect of PCT against apoptosis by nitric 
oxide down-regulation.
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Background
Researchers generally agree that increased procalcitonin (PCT) synthesis is detrimen-
tal to the host because a high concentration of this calcitonine precursor reﬂ  ects the 
severity of sepsis and is predictive of mortality (Bossink et al 1999). Procalcitonin, a 
116 amino acid peptide, is produced physiologically by thyroid C-cells and cleaved 
by speciﬁ  c protease. This prohormone is found at low concentration (0.1 ng/mL) 
in healthy subjects and at high concentration in critically ill patients with a particular 
infection or shock. Although the role and production site of the PCT are unclear, this 
peptide induced by tumor necrosis factor alpha (TNF-α) is currently considered to be 
an effective inﬂ  ammatory marker used to monitor septic shock, pancreatic necrosis, 
or burn injuries (Venet et al 2002).
Recently, our research has focused on how PCT is implicated in acute childhood 
pyelonephritis (AP), followed in 30% of cases by renal ﬁ  brosis (RF) leading to chronic 
sequelae (such arterial hypertension gravidic toxemy). Renal ﬁ  brosis results from 
functional parenchyma disorder consecutive to renal cell apotosis, usually mediated 
by lipopolysaccharide (LPS)-induced TNF-α production. During the infection of the 
renal parenchyma, the bacterial LPS of the membranes induces the release of TNF, 
interleukin-1 (IL1), and IL6 (Oberhoffer et al 1999).
Pro-inﬂ  ammatory TNF-α activates nitric oxide (NO) release, which is catalyzed 
by nitric oxide synthase (NOS) in the presence of Ca2+/calmodulin. Thus intracellular 
calcium concentration is crucial for Ca2+/calmodulin complex formation and NOS 
activation-inducing apoptosis (Arena et al 2002).Infection and Drug Resistance 2008:1 18
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In fact, cell viability and apoptosis depends on the 
spatiotemporal organization of cytosolic Ca++ leading to 
transmembrane polarization magnitude (Lang et al 2005). 
In this context, the renal scintigraphy using the polar 
99mTc-DMSA complex allows parenchyma exploration and 
then monitoring of acute and chronic lesions due to mem-
brane adsorption attenuation (Belhadj-Tahar et al 2000).
The aim of this work is to clarify the physiological 
role of PCT in AP by monitoring the early and later renal 
lesions (edema/ﬁ  brosis) using 99mTc-DMSA parenchyma 
exploration.
Material and methods
This prospective study enrolled 183 children. All subjects 
exhibited clinical and biological infectious syndrome, with 
abdominal or lumbar pains and positive urine culture before 
antibiotherapy administration. All children were treated with 
bi-therapy according to the French consensus on acute pyelo-
nephritis treatment dated November 16, 1990: intravascular 
administration of ceftriaxone 50 mg/kg/day and netromicine 
7 mg/kg/day during the ﬁ  rst 48 hours, followed by speciﬁ  c 
antibiothérapy suited to antibiogram.
On admission C-reactive protein (CRP), phospholipase 
A2, and procalcitonin were measured by the following 
methods: CRP turbidimetric immunoassay (Olympus diag-
nostica, GmbH) PLA2: ﬂ  uometric assay (SFM 25 Kontron 
Instruments) and PCT: luminescent immunoassay (Brahms 
diagnostica GmbH). Procalcitonin in serum were quanti-
ﬁ  ed as well as CRP and phospholipase A2. Scintigraphy 
monitoring with intravascular 99mTc-DMSA (CIS Bio Inter-
national, France) was performed according to MacKenzie 
protocol (MacKenzie 1996) on day 4 and nine months after 
admission in the presence of persistent abnormalities.
The scintigraphic parenchyma lesions were classiﬁ  ed into 
4 categories: absence (stage 0), unique and focal (stage II), 
multiple but unilateral (stage II), and bilateral (stage III).
Results
At day 4, 78% (107/136) had scintigraphic parenchyma 
renal alterations and 30% (17/57) presented renal ﬁ  brosis 
at 9th month. On admission, except for CRP, both PLA2 
and PCT were signiﬁ  cantly higher in patients with early 
scintigrahic alteration (PCT: 7.85 vs 2.36 µg/L and PLA2: 
72.1 vs 29.9 IU/L) (Table1).
Discussion
During the infection of the renal parenchyma, the bacterial 
LPS of the membranes induces the release of TNF, IL1, 
and IL6.
These cytokines are capable of evoking fever, inﬂ  am-
mation syndrome, and cell apoptosis followed by ﬁ  brosis 
(Figure 1).
In the acute phase, IL1 and IL6 induce hepatic produc-
tion of CRP and PLA2 leukocyte release. PLA2 is directly 
implied in the inﬂ  ammatory process including the prosta-
glandins production from arachidonic acid in the presence of 
cyclooxygenase (Diaz 1996). Whereas, procalcitonin CRP 
and PLA2 have weak discriminative power for predictive 
renal ﬁ  brosis regarding to their AUC values below 0.65 
(see Figure 1).
We hypothesized that PCT down-regulates nitric 
oxide (NO) release produced by NO-Synthase activated 
by TNF-α pro-inﬂ  ammatory cytokine (Figure 2). Indeed, 
PCT was paradoxically signiﬁ  cantly lower in the presence 
of chronic renal ﬁ  brosis (4.19 ± 1.03 vs 7.59 ± 3.45 µgL-1). 
We observe a signiﬁ  cant PCT increase in the favorable 
progress (recovery 7.55 ± 4.02 vs aggravation 3.34 ± 1.09) 
and no difference between recovery and improvement evo-
lution. These results suggest the protective effect of PCT 
against apoptosis resulting from down-regulation of nitric 
oxide release catalyzed by NO-synthase (Figure 1) and 
corroborate the previous In vitro observations (Hoffmann 
et al 2003).
Table1 Characteristics of 107 patients with acute childhood pyelonephritis
lesion age Sex ratio CRP (mgL−1) PLA2 (IUL−1) PCT(µgL−1)
4th day Absence 43.48 ± 7.39 n = 29 M: 7%; F: 15% 77.16 ± 10.21 n = 25 29.90 ± 7.83 n = 27 2.36 ± 1.36 n = 23
Stage  0 44.07 ± 4.26 n = 107 M: 29%; F: 71% 114.60 ± 9.74 n = 100 72.03 ± 7.94 n = 87 7.85 ± 1.93 n = 65
Stage I 37.91 ± 4.47 n = 72 M: 15%; F: 38% 114.60 ± 9.0 n = 66 76.32 ± 13.08 n = 57 6.40 ± 1.99 n = 47
Stage II 48.70 ± 7.30 n = 21 M: 5%; F: 10% 130.14 ± 23.36 n = 21 32.70 ± 6.72 n = 17 7.34 ± 4.66 n = 11
Stage III 33.47 ± 8.79 n = 14 M: 1%; F: 9% 121.07 ± 16.46n = 14 104.65 ± 28.47 n = 13 18.37 ± 9.46 n = 7
9th month Absence 39.86 ± 6.78 n = 40 M: 17%; F: 53% 101.16 ± 12.20 n = 37 61.80 ± 12.22 n = 33 7.59 ± 3.45 n = 24
Fibrosis (Stage I) 27.19 ± 5.54 n = 17 M: 7%; F: 23% 123.35 ± 21.35 n = 17 81.65 ± 20.38 n = 13 4.19 ± 1.03 n = 11Infection and Drug Resistance 2008:1 19
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Figure 1 Receiver operating characteristics curves for C-reactive protein (CRP), phospholipase A2 (PLa2), procalcitonin (PCT), and renal ﬁ  brosis observed by 99mTc-DMSA 
scintigraphy.
Note: Areas under curve (AUC) of the 3 markers were respectively (CI: 0.26163–0.72184) for CRP; 0.5475 (CI: 0.33059–0.76445) for PLa2 and 0.6240 (CI: 0.42373–0.82421) 
for PCT.
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Figure 2 Physiopathology of pyelonephritis.
Abbreviations: IL, interleukin; NO, nitric oxide; NOS, NO synthase; PCT, procalcitonin; PLA2, phospholipase A2; CRP, C-reactive protein; FGF, ﬁ  broblast growth factor; TNF, 
tumor necrosis factor.Infection and Drug Resistance 2008:1 20
Belhadj-Tahar et al
Table 2 Pyelonephetis progress according to procalcitonin concentration
No sequellae Fibrosis sequellae F. test
Early lesion stage I–II 7.59 ± 3.45 mgL−1 n = 24 4.19 ± 1.03 mgL−1 n = 11 p  0.001
Recovery stage(0) Aggravation stage ( →I)
Early lesion stage: I 7.55 ± 4.02 mgL−1 n = 20 3.34 ± 1.09 mgL−1 n = 6 p  0.001
recovery stage (0) Improvement stage (II→I)
Early lesion stage:  II 7.78 ± 5.98 mgL−1 n = 4 4.60 ± 2.36 mgL−1 n = 5 ns
Note: The procalcitonin levels are listed according to pyelonephetis progress.
Conclusion
Our study shows that PCT plays key role in the renal paren-
chyma protection against cell apopotosis and ﬁ  brosis caused 
by acute pyelonephritis. this ﬁ  nding constitutes a original 
approach in the comprehension of apoptosis paradigm that 
causes parenchyma ﬁ  brosis.
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